Aegis Maintains Valeant (VRX) at Buy; Win Positive for Anacor (ANAC), Jublia Still on Track
Tweet Send to a Friend
Aegis Capital keeps its Buy rating and $140 target on Valeant Pharma (NYSE: VRX) following an ealier announcement that Valeant ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
